Xencor, Inc. (NASDAQ:XNCR) Director Sells $359,526.03 in Stock

Xencor, Inc. (NASDAQ:XNCR) Director Alan Bruce Montgomery sold 13,301 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $27.03, for a total value of $359,526.03. Following the completion of the transaction, the director now owns 9,140 shares in the company, valued at $247,054.20. This represents a 59.27 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Alan Bruce Montgomery also recently made the following trade(s):

• On Wednesday, December 4th, Alan Bruce Montgomery sold 1,421 shares of Xencor stock. The shares were sold at an average price of $27.03, for a total value of $38,409.63.

Xencor Trading Down 1.5 %

Shares of XNCR stock traded down $0.40 during trading hours on Wednesday, reaching $26.20. The company’s stock had a trading volume of 682,900 shares, compared to its average volume of 608,974. Xencor, Inc. has a fifty-two week low of $15.31 and a fifty-two week high of $27.24. The firm’s 50 day simple moving average is $22.19 and its 200-day simple moving average is $20.56. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.27. The firm had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $14.59 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business’s revenue for the quarter was down 81.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.40) earnings per share. As a group, research analysts predict that Xencor, Inc. will post -3.71 EPS for the current year.

Hedge Funds Weigh In On Xencor

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Linden Thomas Advisory Services LLC increased its holdings in Xencor by 1.6% in the 2nd quarter. Linden Thomas Advisory Services LLC now owns 43,643 shares of the biopharmaceutical company’s stock worth $826,000 after purchasing an additional 699 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Xencor during the second quarter worth about $154,000. Diversified Trust Co increased its stake in shares of Xencor by 7.8% in the second quarter. Diversified Trust Co now owns 14,076 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 1,017 shares during the period. Louisiana State Employees Retirement System boosted its position in Xencor by 3.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company’s stock worth $587,000 after buying an additional 900 shares during the period. Finally, Baillie Gifford & Co. grew its holdings in Xencor by 3.3% during the 2nd quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company’s stock worth $445,000 after acquiring an additional 744 shares during the last quarter.

Analyst Ratings Changes

XNCR has been the topic of a number of analyst reports. Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and increased their price target for the company from $20.00 to $30.00 in a research report on Monday. Royal Bank of Canada lifted their price target on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research report on Thursday, September 26th. Wedbush restated an “outperform” rating and issued a $38.00 price objective on shares of Xencor in a research report on Thursday, November 7th. BMO Capital Markets reiterated an “outperform” rating and set a $34.00 target price (up from $32.00) on shares of Xencor in a report on Friday, November 8th. Finally, JPMorgan Chase & Co. raised their target price on shares of Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $36.50.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.